There has been an increase in demand for caregiver dosage forms over the past two decades. In the oral cavity, mouth dissolving film dissolves swiftly. Oral films that dissolve in your mouth function best when combined with medications that act quickly, such as Xanthine category drugs (Salbutamol Sulphate) and Xanthene Derivative Theophylline. According to the World Health Organization (WHO), asthma affects one in six adults and a quarter of all children, according to the WHO. A child’s admission to the hospital is often due to asthma, which is one of the most prevalent reasons for admission. During an asthma attack, quick-relief or rescue drugs are used to relax and open the airways, as well as ease symptoms. If prescribed, these medications can also be administered prior to exercise. To treat asthma, a combination of Salbutamol Sulfate and Theophylline is available in tablet form under the brand name “Theo-Asthalin.” Oral films seem to be the most efficacious formulation. As a consequence, children with asthma should receive support from drugs given in the form of mouth-dissolving films, since they provide better patient compliance and an appropriate treatment method.

Microencapsulation is a technique that uses a coating to encapsulate microscopic particles or droplets in order to generate miniature capsules with therapeutic properties. The substance contained within the microcapsule is referred to as the core, internal phase, or fill, whereas the wall is referred to as a shell, coating, or membrane. A microcapsule is a small object that contains essential items, internal components, or fillers and is encased by a shell, cover, or membrane. Microcapsules range in size from 1 to 1000 micrometres. This approach is frequently used for medication administration, molecular protection, and robustness. The microencapsulation programme has been established as a different delivery mechanism for multiple treatment regimens and offers potential benefits beyond those of normal medication delivery systems. Microencapsulation is a well-established review dedicated to the preparation, properties, and applications of individually encapsulated novel small particles, as well as significant improvements to tried-and-tested techniques relevant to micro and nano particles and their use in a wide range of industrial, engineering, pharmaceutical, biotechnology, and research applications. Its scope extends beyond conventional microcapsules to all other small particulate systems, such as self-assembling structures that involve preparative manipulation.

By dissolving drug molecules in these solutions, a unit dosage form for oral administration can be generated for oral administration. Self-emulsifying drug delivery system (SEDDS) is utilized to address the inadequate bioavailability of poorly soluble and highly permeable drugs, according to the literature. These methods can disseminate and deliver hydrophobic medications as a unit dose form for oral administration in this fashion. SEDDS formulations self-emulsify (micro/nano) after being discharged into the intestinal lumen and coming into contact with the gastrointestinal (GI) fluid. Several factors must be considered to make the oral drug administration difficult, including poor water solubility and limited permeability. Self-emulsifying drug delivery can increase the solubility of biopharmaceutical classification system (BCS) II medicines. The SEDDS is a drug delivery system that enhances the solubility of lipophilic medications. It has risen in popularity over time. Under moderate agitation and subsequent dilution, GI fluids are categorized as hydrophilic liquid mixes that are isotropic. This research looks at a variety of uses as well as recent advancements in SEDDS composition, evaluation, dosage forms, and novel techniques to convert liquid SEDDS to solids. Final Thoughts Determining whether or not it is feasible to construct a BCS Category 2 medication formulation based on SEDDS represents a significant contribution of this effort. Medicines with solubility issues and low and variable bioavailability will benefit from the connected technologies.

Background of the Study: Intravenous (IV) therapy is an integral part of modern medicine and is practiced in virtually every healthcare setting, dealing with critical and general ailments of a community. Majority of the IV drugs are administered by nurses, who are increasingly involved in the insertion of peripheral vascular access devices. The widespread use of IV therapy can lead to complacency about the risks and may result in poor standards of practice, putting patients at risk of clinical harm and making nurses vulnerable to a claim of negligence. Methodology: In order to achieve the objectives of the study the study design was factorial time series design. The sample consisted of 40 subjects (20 in each group-1 & group-2) who had developed mild symptoms of intravenous complication, selected by convenience sampling technique. In this study the dependent variables were complications of IV cannulation. The independent variables were two modalities of treatment (thrombophob ointment & hot fomentation). The pre-test score was assessed before treatment and treatment was given for two consecutive days. The post-test data were analysed using statistical tests like One-way ANOVA and T-Test. Results:The mean value of pre-test of Group-I is 7.650, the SD is 1.843 and mean value of post test of group-I is 3.633, the SD is 1.070 and the't' value of Group I is 15.325. The obtained 't' value is greater than table value of t (18) = 2.09. So thrombophob with hot fomentation is effective in reducing complications of IV cannulation. The mean value of pre-test of Group -II is 7.950, the SD is 1.637 and mean value of post test of group-II is 4.166, the SD is 0.0861 and the 't' value of Group II is 12.281. The obtained 't' value is greater than table value of t (18) = 2.09. So thrombophob without hot fomentation is effective in reducing complications of IV cannulation. In order to find out the significant difference between the two scores in group I and group II unpaired 't' test value was computed. The obtained 't' value is lower than the table value of T (38)= 2.02. Calculated value is less than the table value so there is no significant difference between the two interventions provided by the researcher. There is no association between the mean differences & the selected background factors among patients on intravenous therapy in experimental group-I & experimental group -II. Interpretation and Conclusion:The investigator had chosen two modalities of treatment to prevent local complications of IV cannulisation. The study reiterated that both the interventions (Thrombophob ointment with & without hot fomentation) are effective in preventing local complications of IV cannulisation. This result should be incorporated practically and introduced as evidenced-based practice to students and nurses.